Novo Nordisk boosts Omeros with licensing deal worth up to $2.1B

[Two coloured ropes knotting together]
Richard Drury/DigitalVision via Getty Images

* Omeros (NASDAQ:OMER [https://seekingalpha.com/symbol/OMER]) shares surged ~138% in the premarket on Wednesday after Novo Nordisk (NVO [https://seekingalpha.com/symbol/NVO]) entered into an asset purchase and license agreement worth up to $2.1B with the Seattle, Washington-based biotech.
* As part of the agreement, the Danish drugmaker is set to obtain exclusive global rights to develop and commercialize an experimental therapy identified as zaltenibart (formerly known as OMS906), which is designed to target rare blood and kidney disorders.
* The antibody therapy has already generated promising Phase 2 results against paroxysmal nocturnal hemoglobinuria, a rare blood disorder. All of its clinical trials have so far indicated a favorable safety profile for the drug, the companies said.
* According to the deal terms, Omeros (NASDAQ:OMER [https://seekingalpha.com/symbol/OMER]) will receive $340M in upfront and near-term milestone payments and up to $2.1B in payments, including development and commercial milestones, in addition to tiered royalties on potential net sales. The transaction is expected to be complete in Q4 2025. [https://seekingalpha.com/pr/20266711-novo-nordisk-and-omeros-announce-asset-purchase-and-license-agreement-for-omeros-clinical]

MORE ON OMEROS, NOVO NORDISK

* Akero: Novo Nordisk Acquisition Puts Focus On Unprecedented MASH Data With EFX [https://seekingalpha.com/article/4829066-akero-novo-nordisk-acquisition-puts-focus-on-unprecedented-mash-data-with-efx]
* Novo Nordisk's Akero Deal: Panic Buy Or Wise Decision? Here's My Take [https://seekingalpha.com/article/4828906-novo-nordisk-akero-deal-panic-buy-or-wise-decision]
* Novo Nordisk to Acquire Akero Therapeutics Inc. [https://seekingalpha.com/article/4828884-novo-nordisk-to-acquire-akero-therapeutics-inc]
* Key deals this week: Protagonist Therapeutics, Bristol Myers, Novo Nordisk, Fifth Third Bancorp and more [https://seekingalpha.com/news/4503442-key-deals-this-week-protagonist-therapeutics-bristol-myers-novo-nordisk-fifth-third-bancorp-and-more]
* Novo Nordisk said to be closing its cell therapy unit [https://seekingalpha.com/news/4503355-novo-nordisk-closing-cell-therapy-unit]